Pipeline
As of November 8, 2022
- Clinical Trial
- Japan
- Outside of Japan
In-house drug discovery
Infectious Diseases
| FYE March 2023 | FYE March 2024 | FYE March 2025 | ||
| OP0595 Nacubactam: [β-lactamase inhibitor] | Phase I with β-Lactams |
Phase III |
More about our work in the field of infectious diseases:
Others
| FYE March 2023 | FYE March 2024 | FYE March 2025 | ||
| HBI-8000 Tucidinostat: [Relapsed or refractory peripheral T-cell lymphoma (PTCL)] *1 | Approved | blank | ||
| ME3208 Belumosudil: [Chronic Graft Versus Host Disease] *2 | Phase III | Apply | Approve | |
| DMB-3115 Ustekinumab biosimilar: [Plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis] *3 | Phase III | Apply | Approve | |
| Phase I | Apply | Approve | ||
| ME3183: [Psoriasis/Selective PDE4 inhibitor] | Phase IIa | Phase IIb | ||
| HBI-8000 Tucidinostat: [Relapsed or refractory B-cell non-Hodgkin's lymphoma] *4 | Phase Ib/II | |||
| DMB-3111 Trastuzumab biosimilar: [Breast cancer, Gastric cancer] *5 | (P I finished) |
Vaccines
| FYE March 2023 | FYE March 2024 | FYE March 2025 | ||
| KD-370: [Pentavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, and haemophilus influenza type b] | Phase III | Applied | Approve | |
| Phase II | blank | |||
| KD-414: [Inactivated vaccine against COVID-19] | Phase I / II | |||
| Phase II / III | ||||
| Phase II/III (Pediatric Clinical Trials) |
||||
| Phase III (Adults under 40) *6 |
||||
| KD-404: [Egg-derived inactivated whole virus influenza vaccine] *7 | Phase I / II |
|||
| KD-382: [Quadrivalent vaccine against dengue fever] | Phase I | |||
| KD2-396: [Pentavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, haemophilus influenza type b, and Hepatitis B virus] | Phase I |
More about our work in the field of vaccines:
Blood Plasma Products
| FYE March 2023 | FYE March 2024 | FYE March 2025 | ||
| KD2-305: [Suppression of bleeding tendency in patients with blood coagulation factor VIII or factor IX deficiency who have coagulation factor inhibitors] | Applied | Approved | ||
| Extension study | blank |
More about our work in the field of blood plasma:
Veterinary Drugs
| FYE March 2023 | FYE March 2024 | FYE March 2025 | ||
| ME4137: [Injectable antibacterial drugs for cattle use] | Applied | Approve | ||
| ME4137: [Injectable antibacterial drugs for swine use] | Applied | Approve | ||
| ME4406: [Feed additive] | Apply | |||
| ME4305: [Antibacterial drugs for cattle use] | Apply | |||
| KD-412: [Vaccine for cattle use] | Applied | Approve | ||
| MD-1001-1: [Injectable antibacterial drugs for cattle use] | Apply |
More about our work in the field of veterinary drugs:
Related Links
Have a question?
Contact us here.
CONTACT US
Meiji Seika Pharma Co., Ltd.
Based in Japan, we are a leading developer and manufacturer of antibacterial drugs, vaccines and biotech solutions, with a history of over 75 years.
Location
- Headquarters
2-4-16 Kyobashi, Chuo-ku, Tokyo104-8002 Japan